Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for SNY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for SNY and 80,000+ other tickers.
See exactly how SNY's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SNY and 80,000+ other tickers.
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and…
Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8% dividend yield. I see SNY pipeline risks as overstated; Dupixent's expansion and multiple smaller launches provide solid growth through 2028E. Even with no new blockbusters, SNY offers 15%+ annualized upside at normalized EPS and historical multiples, supporting a strong value thesis.
CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure ver.
Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany.
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027